About Us
Our Team Practice Manifesto Our Approach Awards & Accolades Landmark SEC Lawsuit
SEC Whistleblower Program
Program Fundamentals SEC Tips Process Facts & Figures SEC Whistleblower Awards Common Securities Violations International Whistleblowers SEC Whistleblower Resources Eligibility Calculator
Clients & Results
Our Whistleblower Cases Our Clients SEC Prosecutions Private Securities Cases Whistleblower Advocacy
News & Insights
Articles & Perspectives In The News Reports & Surveys Rules & Regs Webinars, Videos & Podcasts
Resources
Securities Law Primer Eligibility Calculator SEC Insiders Guide SEC Whistleblower Handbook Sanctions Database FAQ
SEC
Whistleblower
Attorneys
Landmark Lawsuit Filed Against SEC to Protect Future Whistleblowers
About Us
Our Team Practice Manifesto Our Approach Awards & Accolades Landmark SEC Lawsuit
SEC Whistleblower Program
Program Fundamentals SEC Tips Process Facts & Figures SEC Whistleblower Awards Common Securities Violations International Whistleblowers SEC Whistleblower Resources Eligibility Calculator
Clients & Results
Our Whistleblower Cases Our Clients SEC Prosecutions Private Securities Cases Whistleblower Advocacy
Insights
All News & Insights Articles & Perspectives In The News Reports & Surveys Rules & Regs Webinars, Videos & Podcasts
Resources
Securities Law Primer Eligibility Calculator SEC Insiders Guide SEC Whistleblower Handbook Sanctions Database FAQ

June 05, 2020

Stiefel Laboratories Inc., Charles W. Stiefel

Trading and Pricing

SANCTION AMOUNT: $37000000

Defendants: Stiefel Laboratories Inc.
Charles W. Stiefel

Company and its former Chairman/CEO consented to entry of final judgment in case alleging that they conducted share buybacks (mostly from employees) without disclosing negotiations with GlaxoSmithKline PLC that resulted in an acquisition at a share price more than four times higher than the buyback price.

Find more cases
Named one of the top whistleblower practices/attorneys in the country by The New York Times, Wall Street Journal and NPR
Stay in touch
New York   (212) 907-0700
Washington, D.C.   (202) 772-1880
Delaware   (302) 573-2540
Copyright © 2021 Labaton Sucharow LLP. All rights reserved.
Privacy Policy   |   Attorney Advertising Disclaimer
Stay in touch
Thank you for submitting some email to us.